Evotec, HSCI Ink ALS Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Evotec today said that it has forged an alliance with the Harvard Stem Cell Institute to identify compounds that can prevent or slow down the loss of motor neurons, a characteristic of amyotrophic lateral sclerosis.

The collaboration, dubbed CureMN, or CureMotorNeuron, will leverage Evotec's drug discovery infrastructure and expertise in identifying compounds with therapeutic value, as well as human motor neuron assays based on ALS patient-derived induced pluripotent stem cells developed by HSCI principal faculty members Lee Rubin and Kevin Eggan.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.